Drug Exposure During Pregnancy in Abbvie Inc Drugs

2 drug(s) with this reaction

1,312 total reports

Overview

Drug Exposure During Pregnancy has been reported as an adverse reaction across 2 drug(s) manufactured by Abbvie Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 1,312 adverse event reports mention drug exposure during pregnancy in connection with Abbvie Inc products.

This page provides a breakdown of which Abbvie Inc drugs are most commonly associated with drug exposure during pregnancy, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.

Abbvie Inc Drugs Reporting Drug Exposure During Pregnancy

The following Abbvie Inc drugs have drug exposure during pregnancy listed in their FDA adverse event reports, sorted by report count:

Other Reactions Reported for Abbvie Inc Drugs

In addition to drug exposure during pregnancy, the following adverse reactions have been reported across Abbvie Inc's drug portfolio:

DRUG INEFFECTIVEPAINARTHRALGIAINJECTION SITE PAINFATIGUERHEUMATOID ARTHRITISHEADACHENAUSEADIARRHOEARASHPSORIASISPAIN IN EXTREMITYJOINT SWELLINGINCORRECT DOSE ADMINISTEREDMALAISEOFF LABEL USENASOPHARYNGITISCROHN^S DISEASEPYREXIADEVICE ISSUE

Frequently Asked Questions

Which Abbvie Inc drugs cause Drug Exposure During Pregnancy?

2 drug(s) manufactured by Abbvie Inc have drug exposure during pregnancy listed in their FDA adverse event reports: LOPINAVIR AND RITONAVIR, RITONAVIR.

How many Drug Exposure During Pregnancy reports are there for Abbvie Inc drugs?

There are a combined 1,312 reports of drug exposure during pregnancy across 2 Abbvie Inc drug(s) in the FDA adverse event database.

Disclaimer: This analysis is based on FDA adverse event reports and is for informational purposes only. Reports do not prove causation. Always consult your healthcare provider.